• Terms and Conditions
  • Privacy Policy
  • DMCA
  • Disclaimer
  • Cookie Privacy Policy
  • Contact Us
Sixsense News
Advertisement
  • Home
  • Business
  • Economy
  • Fintech
  • Finance
  • Insurance
  • Market
  • Startups
No Result
View All Result
  • Home
  • Business
  • Economy
  • Fintech
  • Finance
  • Insurance
  • Market
  • Startups
No Result
View All Result
Sixsense News
No Result
View All Result
Home Market

Roche’s test wins FDA nod to identify certain breast cancer patients eligible for Enhertu

Sixsense News by Sixsense News
October 4, 2022
in Market
0


trabantos/iStock via Getty Images

The U.S. Food and Drug Administration (FDA) approved Roche’s (OTCQX:RHHBY) (OTCQX:RHHBF) PATHWAY anti-HER2/neu (4B5) Rabbit Monoclonal Primary Antibody test to identify patients with metastatic breast cancer with low HER2 expression for whom Enhertu can be used as a targeted treatment.

The test is the only FDA approved companion diagnostic indicated to assess HER2 low status in patients with metastatic breast cancer, the company said in an Oct. 4 press release.

The Swiss pharma giant added that the FDA approval of the new HER2 low indication expands on the intended use of its on-market PATHWAY anti-HER2 (4B5) test.

The test was used as part of a study called DESTINY-Breast04 by AstraZeneca (AZN) and Daiichi Sankyo (OTCPK:DSKYF) (OTCPK:DSNKY), the developers of Enhertu (fam-trastuzumab deruxtecan-nxki), to identify patients whose tumors expressed low levels of HER2 protein, Roche added.

A companion diagnostic is a test that helps determine if a particular therapy’s benefit to patients will outweigh any potential serious side effects or risks, and also helps identify patients who are more likely to benefit from a particular drug, according to the FDA.

In August, the FDA approved Guardant Health’s (GH) liquid biopsy test Guardant360 CDx as a companion diagnostic to to identify patients with a type lung cancer who could be treated with Enhertu.



Source link

Related articles

largecap stock ideas: How Kotak Equities tweaked its largecap portfolio

September 22, 2023

9 Money Mistakes Setting Fire to Your Future

September 22, 2023
Tags: breastcancereligibleEnhertuFDAidentifynodpatientsRochesTestwins

Related Posts

largecap stock ideas: How Kotak Equities tweaked its largecap portfolio

by Sixsense News
September 22, 2023
0

Brokerage Kotak Institutional Equities has increased its weight on consumer plays Britannia Industries and Godrej Consumer Products (GCPL) as it...

9 Money Mistakes Setting Fire to Your Future

by Mike Brassfield
September 22, 2023
0

schankz / Shutterstock.comAdvertising Disclosure: When you buy something by clicking links on our site, we may earn a small commission,...

Strike ends at Chevron’s Australian LNG facilities By Reuters

by Reuters
September 22, 2023
0

© Reuters. FILE PHOTO: A 3D printed natural gas pipeline is placed in front of displayed Chevron logo in this...

tesla india entry: Buzz over Tesla’s India entry leaves investors excited. Which auto stocks could be in focus?

by Sixsense News
September 22, 2023
0

With Tesla's India entry being a question of when, not if, Dalal Street investors have found another reason to turn...

Did High Interest Rates Kill House Flipping?

by On The Market Podcast Presented by Fundrise
September 22, 2023
0

House flipping profits are off the charts, so why are so many house flippers leaving the market? Top flippers like...

Load More

largecap stock ideas: How Kotak Equities tweaked its largecap portfolio

September 22, 2023

Fevertree Drinks: Disappointing Performance On Top Of Weak Growth Outlook (OTCMKTS:FQVTF)

September 22, 2023

‘Make in India’ iPhones now out as hundreds queue up to own new Apple devices

September 22, 2023

9 Money Mistakes Setting Fire to Your Future

September 22, 2023

Australia stocks higher at close of trade; S&P/ASX 200 up 0.05% By Investing.com

September 22, 2023

Investec predicts higher H1 pretax profit driven by UK, South African performance By Investing.com

September 22, 2023
Sixsense News

© 2022 Sixsense News All Rights Reserved.

Navigate Site

  • Terms and Conditions
  • Privacy Policy
  • DMCA
  • Disclaimer
  • Cookie Privacy Policy
  • Contact Us

Follow Us

No Result
View All Result
  • #3158 (no title)
  • Business
  • Economy
  • Finance
  • Fintech
  • Insurance
  • Market
  • Startups

© 2022 Sixsense News All Rights Reserved.